Dr. Chapple’s primary role as Director of Biostatistics is planning cancer clinical trials in mice, humans, and cell lines – while also executing statistical analyses. Dr. Chapple is an expert in adaptive clinical trial designs, particularly Bayesian methods. His 2019 paper “A hybrid Phase I-II/III clinical trial design allowing for dose re-optimization in Phase III” proposed a new framework for seamless drug development through the three stages of clinical trial design. This paper was recognized by the statistical community when it received the award for “Best Paper” from Biometrics, a top tier statistical journal. Dr. Chapple hopes this expertise can propel his institution towards innovative cancer therapies, rapid advances in treatment of chronic diseases, and the long-term goal of personalized/precision medicine.
Dr. Chapple has produced many new trial designs and methods, which are accompanied with user-friendly R packages. Dr. Chapple trained under Dr. Peter Thall at MD Anderson, who is a pioneer in Bayesian adaptive trials. He later refined these skills working with cancer researchers from other institutions. Dr. Chapple’s adaptive trial designs were used to dose-find in pediatric brain tumors in atrial conducted at Harvard and the Dana Farber Cancer Center.
Dr. Chapple has designed hundreds of studies and has supported many research departments at LSUHSC including Orthopedics, OBGYN, Hematology Oncology, Dermatology, Oral Surgery, Endodontics, Cancer, Virology, Cellular Biology, Inflammation, and treatment disparities research. As a joint professor in Orthopedics, Dr. Chapple works on large scale electronic records databases which requires processing longitudinal information from patients on hospital encounters, diagnoses, procedures, prescriptions, and lab values.
Undergraduate:
B.S. Louisiana State University,May 2012
Major: Mathematics
Graduate:
M.Ap.St, Louisiana State University, May2014
Major: Applied Statistics
Ph.D., Rice University, May 2018
M.S., Rice University, May 2018
Major: Statistics
ORCID identifier
https://orcid.org/0000-0001-5332-2730
MyNCBI Link
https://pubmed.ncbi.nlm.nih.gov/?term=andrew%20chapple
Selected Publications
Chapple AG, Thall PF.(2018). A Hybrid Phase I-II/III Clinical Trial Design Allowing DoseRe-Optimization in Phase III. Biometrics. PMCID: PMC6486466
Chapple AG, Thall PF.(2018). Subgroup-specific dose finding in phase I clinical trials based ontime to toxicity allowing adaptive subgroup combination. Journal of PharmaceuticalStatistics. 1-16.PMCID: PMC6640643
Chapple, A. (2020). Bayesian subgroup clustering inphase I clinical trials. SAGEResearch Methods Cases. doi: https://dx.doi.org/10.4135/9781529742657
Chapple,AG, Peak, T, Hemal, A. A novel Bayesian continuous piecewise linear log‐hazardmodel, with estimation and inference via reversible jump Markov chain MonteCarlo. Statisticsin Medicine. 2020; 1– 15. https://doi.org/10.1002/sim.8511. PMID: 32086957
Salomon, B, Krause, P.C., Dasa, V., Hall, L.,Shi, L., Chapple, AG (2021). Hospitallength of stay is associated with increased likelihood for venousthromboembolism following total joint arthroplasty. Arthroplasty today. https://doi.org/10.1016/j.artd.2020.12.025
CameronJ.E., Dennis D.C., Herrel N.R., Chapple AG, and Hagensee ME(2020). Risk of abnormal cervical cytology in HIV-infected women testingpositive for both human papillomavirus and Epstein-Barr virus in genital tractspecimens. Cancer Causes and Control. 31(4): 365-375. PMCID: PMC8432267
Christensen,B.J., Chapple, AG, King, B.J. (2019). What is the Effect of TreatingMandibular Fractures on Weight and Prealbumin? Journal of Oral andMaxillofacial Surgery. 77 (6): 1-6. PMID: 30851249
PeakT.C., Chapple, AG, Coon, G., Hemal, A. (2018). Utilizing aSemi-Competing Risk Model to Predict Perioperative and Oncologic Outcomes afterRadical Cystectomy. British Urology Journal. 10 (11): 317-326. PMCID: PMC6180382
Keywords/Tags
Statistics, Clinical Trials, Bayesian Analysis, Biostatistics
